Loss of Heterozygosity on Chromosome 11p15.5 and Relapse in Hepatoblastomas

Abstract

Background: IGF2 is a tumor suppressor gene at locus 11p15. Many hepatoblastomas have loss of heterozygosity (LOH) at this locus. Earlier studies have not demonstrated any association between LOH and prognosis. Aim of the study was to evaluate the prognostic significance of LOH at 11p15.5 in hepatoblastomas.

Methods: DNA was isolated from normal liver and tumor tissue in 20 patients with hepatoblastoma. PCR was performed and cases were classified as LOH present, absent or non-informative. Patients’ follow-up data was analyzed using Fischer's exact test and Kaplan-Meier survival analysis for relapse-free survival (RFS) in relation to LOH. Ethical clearance was obtained from the institutional ethics board.

Results: All cases were informative for at least one microsatellite marker used. 4 of the 20 cases (20%) had LOH at 11p15.5. One patient died in the immediate postoperative period. 5 of 19 patients relapsed (26%). Of 4 patients who had LOH, 3 (75%) relapsed, the time to relapse being 7, 7 and 9 months, respectively. Of the 15 cases without LOH, 2 (13.3%) relapsed. 4 patients had mixed epithelial and mesenchymal histology; 3 of them had LOH. The 2 groups with and without LOH were well matched. The RFS for patients with LOH (n=4) was 13% (mean survival time [MST]: 8.7 months; 95CI 6.7–10.7), while the RFS for cases without LOH (n=15) was 75% (MST: 100.7 months; 95CI 74.5–126.8).

Conclusion: Mixed epithelial and mesenchymal histology is more frequently associated with LOH on chromosome 11p15.5 than pure epithelial histology. LOH on chromosome 11p15.5 is associated with a significantly increased incidence of relapse and a significantly shorter relapse-free survival in patients with hepatoblastoma. The risk of relapse is higher and the RFS lower both in standard-risk and high-risk patients with hepatoblastoma if they demonstrate the presence of LOH at 11p15.5.

Key words

loss of heterozygosity - relapse - hepatoblastoma

References

• 1 Herzog CE, Andrassy RJ, Eftekhari F. Childhood cancers: Hepatoblastoma.  Oncologist. 2000;  5 445-453
• 2 Pritchard J, Brown J, Shafford E. et al . Cisplatin, doxorubicin and delayed surgery for childhood hepatoblastoma: a successful approach – Results of the first prospective study of the International Society of Pediatric Oncology.  J Clin Oncol. 2000;  18 3819-3828
• 3 Bajpai M, Pal K, Agarwala S. et al . Midterm results with hepatectomy after preoperative chemotherapy in hepatoblastoma.  Pediatr Surg Int. 2005;  21 364-368
• 4 Hartmann W, Waha A, Koch A. et al . p57kip2 is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57kip2, IGF II, and H19.  Am J Pathol. 2000;  157 1393-1403
• 5 Roebuck DJ, Aronson D, Clapuyt P. et al . International Childhood Liver Tumor Strategy Group. 2005 PRETEXT: A revised staging system for primary malignant liver tumors of childhood as developed by SIOPEL group.  Pediatr Radiol. 2007;  37 123-132
• 6 Brown J, Perilongo G, Shafford E. et al . Pretreatment prognostic factors for children with hepatoblastoma – Results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1.  Eur J Cancer. 2000;  36 (11) 1418-1425
• 7 Perilongo G, Shafford E, Maibach R. et al . International Society of Paediatric Oncology-SIOPEL 2. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology – SIOPEL 2.  Eur J Cancer. 2004;  40 (3) 411-421
• 8 von Schweinitz D, Kraus JA, Albrecht S. et al . Prognostic impact of molecular genetics in hepatoblastoma.  Med Pediatr Oncol. 2002;  38 104-108
• 9 Suzuki M, Kato M, Yuyan C. et al . Whole-genome profiling of chromosomal aberrations in hepatoblastoma using high-density single-nucleotide polymorphism genotyping microarrays.  Cancer Sci. 2008;  99 (3) 564-570
• 10 Albrecht S, von Schweinitz D, Waha A. et al . Loss of maternal alleles on chromosome arm 11p in hepatoblastoma.  Cancer Res. 1994;  54 5041-5044
• 11 von Schweinitz D, Hecker H, Schmidt-von-Arndt G. et al . Prognostic factors and staging systems in childhood hepatoblastoma.  Int J Cancer. 1997;  74 593-599
• 12 Fuchs J, Rydzynski J, von Schweinitz D. et al . Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German cooperative pediatric liver tumor study HB 94.  Cancer. 2002;  95 172-182

Correspondence